TransCode Therapeutics
RNAZ
1 hedge funds and large institutions have $2.66M invested in TransCode Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
301% more capital inflows, than outflows
Capital inflows: $3.22M | Capital outflows: $803K
7.62% more ownership
Funds ownership: 8.44% → 16.06% (+7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kepos Capital
New York
|
-$792K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11K |
RNAZ Hedge Fund Activity: Q2 2022 in Review
1 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q2 2022, worth a combined $2.66M — down 15% from $3.14M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RNAZ positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $3.22M. The largest seller was Kepos Capital, cutting an estimated $792K.
- 1 institutional investor held TransCode Therapeutics (RNAZ) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $2.66M of TransCode Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
- 1 fund opened new TransCode Therapeutics positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest TransCode Therapeutics buyer in Q2 2022 was AIGH Capital Management, an estimated $3.22M added.
- The largest TransCode Therapeutics seller in Q2 2022 was Kepos Capital, an estimated $792K sold.
Based on aggregated 13F filings for Q2 2022.